• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Codex DNA Inc. (Amendment)

    7/5/23 1:28:27 PM ET
    $DNAY
    Medical Specialities
    Health Care
    Get the next $DNAY alert in real time by email
    SC 13G/A 1 d852141dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Telesis Bio Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

    192003 101

    (CUSIP Number)

    June 5, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 192003 101

     

      1.    

      Names of Reporting Persons.

     

      BroadOak Fund IV, LLC

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power

     

      0

       6.  

      Shared Voting Power

     

      4,434,730

       7.  

      Sole Dispositive Power

     

      0

       8.  

      Shared Dispositive Power

     

      4,434,730

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

       4,434,730 (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      10.35%

    12.  

      Type of Reporting Person (See Instructions)

     

      PN

     

    (1)

    Includes: (i) 2,319,045 shares of outstanding Common Stock, (ii) 20,000 shares of Redeemable Convertible Preferred Stock, which is convertible into 846,274 shares of Common Stock (assuming a Conversion Price of $2.3633, which is the Conversion Price currently in effect for the Redeemable Convertible Preferred Stock), (iii) Short-term Warrants to purchase 423,137 shares of Common Stock, which are immediately exerciseable, and (iv) Long-term Warrants to purchase 846,274 shares of Common Stock, which are immediately exerciseable.


    CUSIP No. 192003 101

     

      1.    

      Names of Reporting Persons.

     

      BroadOak Asset Management, LLC

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power

     

      0

       6.  

      Shared Voting Power

     

      4,434,730

       7.  

      Sole Dispositive Power

     

      0

       8.  

      Shared Dispositive Power

     

      4,434,730

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

       4,434,730 (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      10.35%

    12.  

      Type of Reporting Person (See Instructions)

     

      IA

     

    (1)

    Includes: (i) 2,319,045 shares of outstanding Common Stock, (ii) 20,000 shares of Redeemable Convertible Preferred Stock, which is convertible into 846,274 shares of Common Stock (assuming a Conversion Price of $2.3633, which is the Conversion Price currently in effect for the Redeemable Convertible Preferred Stock), (iii) Short-term Warrants to purchase 423,137 shares of Common Stock, which are immediately exerciseable, and (iv) Long-term Warrants to purchase 846,274 shares of Common Stock, which are immediately exerciseable.


    CUSIP No. 192003 101

     

      1.    

      Names of Reporting Persons.

     

      BroadOak Capital Partners, LLC

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power

     

      0

       6.  

      Shared Voting Power

     

      4,434,730

       7.  

      Sole Dispositive Power

     

      0

       8.  

      Shared Dispositive Power

     

      4,434,730

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

       4,434,730 (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      10.35%

    12.  

      Type of Reporting Person (See Instructions)

     

      IA

     

    (1)

    Includes: (i) 2,319,045 shares of outstanding Common Stock, (ii) 20,000 shares of Redeemable Convertible Preferred Stock, which is convertible into 846,274 shares of Common Stock (assuming a Conversion Price of $2.3633, which is the Conversion Price currently in effect for the Redeemable Convertible Preferred Stock), (iii) Short-term Warrants to purchase 423,137 shares of Common Stock, which are immediately exerciseable, and (iv) Long-term Warrants to purchase 846,274 shares of Common Stock, which are immediately exerciseable.


    CUSIP No. 192003 101

     

      1.    

      Names of Reporting Persons.

     

      William F. Snider

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

      (a)  ☐        (b)  ☐

     

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      United States of America

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With:

       5.    

      Sole Voting Power

     

      0

       6.  

      Shared Voting Power

     

      4,434,730

       7.  

      Sole Dispositive Power

     

      0

       8.  

      Shared Dispositive Power

     

      4,434,730

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

       4,434,730 (1)

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      10.35%

    12.  

      Type of Reporting Person (See Instructions)

     

      IN

     

    (1)

    Includes: (i) 2,319,045 shares of outstanding Common Stock, (ii) 20,000 shares of Redeemable Convertible Preferred Stock, which is convertible into 846,274 shares of Common Stock (assuming a Conversion Price of $2.3633, which is the Conversion Price currently in effect for the Redeemable Convertible Preferred Stock), (iii) Short-term Warrants to purchase 423,137 shares of Common Stock, which are immediately exerciseable, and (iv) Long-term Warrants to purchase 846,274 shares of Common Stock, which are immediately exerciseable.


    Item 1(a)

    Name of Issuer:

    Telesis Bio Inc.

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices:

    10431 Wateridge Circle

    Suite 150

    San Diego, CA 92121-2993

     

    Item 2

    (a) Name of Person Filing:

    This Schedule 13G is filed by:

     

      (i)

    BroadOak Fund IV, LLC;

     

      (ii)

    BroadOak Asset Management, LLC, the manager and general partner of BroadOak Fund IV, LLC;

     

      (iii)

    BroadOak Capital Partners, LLC, the managing member of BroadOak Asset Management, LLC; and

     

      (iv)

    William F. Snider, a partner and manager of BroadOak Capital Partners, LLC.

     

    Item 2

    (b) Address of Principal Business Office or, if none, Residence:

    The address of the principal business office of each of each Reporting Person is:

    4800 Montgomery Lane

    Suite 230

    Bethesda, MD 20814

     

    Item 2

    (c) Citizenship:

    BroadOak Fund IV, LLC is a Delaware limited liability company.

    BroadOak Asset Management, LLC is a Delaware limited liability company.

    BroadOak Capital Partners, LLC is a Delaware limited liability company.

    William F. Snider s a United States citizen.

     

    Item 2

    (d) Title of Class of Securities:

    Common Stock, $0.0001 par value

     

    Item 2

    (e) CUSIP Number:

    192003 101


    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c).

    Not applicable.

     

    Item 4.

    Ownership.

     

    (a)

    Amount beneficially owned: See Item 9 of the cover page for each Reporting Person.

     

    (b)

    The Reporting Persons may each be deemed the beneficial owner of 10.35% of the Common Stock outstanding, based on the Reporting Persons owning (i) 2,319,045 shares of outstanding Common Stock, (ii) 20,000 shares of Redeemable Convertible Preferred Stock, which is convertible into 846,274 shares of Common Stock (assuming a Conversion Price of $2.3633, which is the Conversion Price currently in effect for the Redeemable Convertible Preferred Stock), (iii) Short-term Warrants to purchase 423,137 shares of Common Stock, which are immediately exerciseable, and (iv) Long-term Warrants to purchase 846,274 shares of Common Stock, which are immediately exerciseable. The number of shares of Common Stock outstanding is based on (i) 29,731,920 shares of Common Stock outstanding, as reported in that certain Redeemable Convertible Preferred Stock and Warrant Purchase Agreement dated as of May 31, 2023, (ii) 11,847,840 shares of Common Stock currently underlying the shares of Redeemable Convertible Preferred Stock (assuming a Conversion Price of $2.3633, which is the Conversion Price currently in effect for the Redeemable Convertible Preferred Stock), (iii) the 423,137 shares of Common Stock issuable upon exercise of the Reporting Person’s Short-term Warrants and (iv) the 846,274 shares of Common Stock issuable upon exercise of the Reporting Persons’ Long-term Warrants.

    (c)     (i)        Sole power to vote or direct the vote:

    See Item 5 of the cover page for each Reporting Person.

     

      (ii)

    Shared power to vote or direct the vote:

    See Item 6 of the cover page for each Reporting Person.

     

      (iii)

    Sole power to dispose or direct the disposition:

    See Item 7 of the cover page for each Reporting Person.

     

      (iv)

    Shared power to dispose or direct the disposition:

    See Item 8 of the cover page for each Reporting Person.

     

    Item 5.

    Ownership of 5 Percent or Less of a Class.

    Not applicable.

     

    Item 6.

    Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

    Not applicable.

    Item 8. Identification and Classification of Members of the Group.

    Not applicable.


    Item 9.

    Notice of Dissolution of Group.

    Not applicable.

     

    Item 10.

    Certifications.

    Not applicable.


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: July 5, 2023

     

    BroadOak Fund IV, LLC
    By:  

    /s/ William F. Snider

    William F. Snider
    Authorized Signatory
    BroadOak Asset Management, LLC
    By:  

    /s/ William F. Snider

    William F. Snider
    Authorized Signatory
    BroadOak Capital Partners, LLC
    By:  

    /s/ William F. Snider

    William F. Snider
    Authorized Signatory
    William F. Snider
    By:  

    /s/ William F. Snider


    Exhibit Index

     

    Exhibit No.

      

    Description

    99.1    Joint Filing Agreement, dated February 17, 2022 (incorporated by reference to Exhibit 99.1 of the Reporting Persons’ Schedule 13G filed with the Securities and Exchange Commission on February 17, 2022).
    Get the next $DNAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DNAY

    DatePrice TargetRatingAnalyst
    3/2/2022Outperform
    Cowen
    10/15/2021Outperform
    Cowen
    7/13/2021$23.00Buy
    Jefferies
    7/13/2021Outperform
    Cowen & Co.
    7/13/2021$30.00Overweight
    Keybanc
    More analyst ratings

    $DNAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Telesis Bio Pre-Announces Preliminary Fourth Quarter Financial Results

      -- Record revenue of $9M in 4QFY22; Increase of 191% over 4QFY21 -- BioXp® Revenue increased by 131% to $3M, in 4QFY22 over 4QFY21 -- Successful achievement of first technical milestone with Pfizer leveraging Telesis Bio's SOLA platform for enzymatic DNA synthesis technology SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today pre-announced certain preliminary, unaudited financial results for the fourth quarter ended December 31, 2022. The results are subject to the completion of the Company's year-end financial reporting processes, reviews, and audit. Telesis Bio also announced that it has a

      1/9/23 9:00:00 AM ET
      $DNAY
      $TBIO
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio Inc. Reports Third Quarter 2022 Financial Results

      -- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:DNAY), a company enabling customers to accelerate the reading and writing of biology, today reported financial results and business highlights for the third quarter ended September 30, 2022. "We are continuing to execute to our plan of being the leader in benchtop automation for synthetic biology, multiomics and next gen sequencing," said Todd R. Nelson, Ph.D., CEO and Founder of Te

      11/8/22 4:10:00 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8

      SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction with the release, management will host a conference call the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investors section of Telesis Bio's website at www.codexdna.com. The conference call can be accessed by registering at the following link: https://register.veve

      11/2/22 4:19:04 PM ET
      $DNAY
      Medical Specialities
      Health Care

    $DNAY
    SEC Filings

    See more
    • Codex DNA Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Telesis Bio Inc. (0001850079) (Filer)

      11/30/23 5:00:12 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • SEC Form 10-Q filed by Codex DNA Inc.

      10-Q - Telesis Bio Inc. (0001850079) (Filer)

      11/13/23 4:32:50 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • Codex DNA Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Telesis Bio Inc. (0001850079) (Filer)

      11/13/23 4:32:03 PM ET
      $DNAY
      Medical Specialities
      Health Care

    $DNAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cowen resumed coverage on Codex DNA

      Cowen resumed coverage of Codex DNA with a rating of Outperform

      3/2/22 8:41:22 AM ET
      $DNAY
      Medical Specialities
      Health Care
    • Cowen resumed coverage on Codex DNA

      Cowen resumed coverage of Codex DNA with a rating of Outperform

      10/15/21 7:20:31 AM ET
      $DNAY
      Medical Specialities
      Health Care
    • Jefferies initiated coverage on Codex DNA with a new price target

      Jefferies initiated coverage of Codex DNA with a rating of Buy and set a new price target of $23.00

      7/13/21 6:31:09 AM ET
      $DNAY
      Medical Specialities
      Health Care

    $DNAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Codex DNA Inc. (Amendment)

      SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)

      7/5/23 1:28:27 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Codex DNA Inc. (Amendment)

      SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)

      7/5/23 1:24:55 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • SEC Form SC 13D filed by Codex DNA Inc.

      SC 13D - Telesis Bio Inc. (0001850079) (Subject)

      6/15/23 4:17:49 PM ET
      $DNAY
      Medical Specialities
      Health Care

    $DNAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Kullback William J

      4 - Telesis Bio Inc. (0001850079) (Issuer)

      12/5/23 4:38:19 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Kullback William J

      3 - Telesis Bio Inc. (0001850079) (Issuer)

      12/5/23 4:36:40 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • Herrema Gregory J. was granted 153,191 shares (SEC Form 4)

      4 - Telesis Bio Inc. (0001850079) (Issuer)

      10/25/23 2:46:10 PM ET
      $DNAY
      Medical Specialities
      Health Care

    $DNAY
    Financials

    Live finance-specific insights

    See more
    • Telesis Bio Inc. Reports Third Quarter 2022 Financial Results

      -- Record revenue of $6.7M in 3QFY22; Increase of 140% over $2.8M 3QFY 2021 -- BioXp® Kit Revenue increased to $884k, or 69% in 3QFY22 over 3QFY2021 -- Increases revenue guidance to $23 million to $25 million for the full year fiscal 2022 SAN DIEGO, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:DNAY), a company enabling customers to accelerate the reading and writing of biology, today reported financial results and business highlights for the third quarter ended September 30, 2022. "We are continuing to execute to our plan of being the leader in benchtop automation for synthetic biology, multiomics and next gen sequencing," said Todd R. Nelson, Ph.D., CEO and Founder of Te

      11/8/22 4:10:00 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • Telesis Bio to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 8

      SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (NASDAQ:DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction with the release, management will host a conference call the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be accessed via the Investors section of Telesis Bio's website at www.codexdna.com. The conference call can be accessed by registering at the following link: https://register.veve

      11/2/22 4:19:04 PM ET
      $DNAY
      Medical Specialities
      Health Care
    • Codex DNA Reports Second Quarter 2022 Financial Results

      SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (NASDAQ:DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June 30, 2022. Recent HighlightsContinued execution across all areas of the growth strategy: Increased total revenue by 98% over prior year periodGrew revenue by 44% on an organic basis year over year, excluding contributions from Eton Bioscience acquisitionDelivered solid growth in BioXp 3250 instrument placementsExperienced record high BioXp kit revenues, driven by growth in gene fragments, cloning, and DNA library kitsLaunched MyBioXperience, a new e-commerce solution, which dramatically sim

      8/9/22 4:10:00 PM ET
      $DNAY
      Medical Specialities
      Health Care